<DOC>
	<DOCNO>NCT00617539</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study side effect give irinotecan together temozolomide see well work treat patient breast cancer receive previous treatment brain metastasis .</brief_summary>
	<brief_title>Irinotecan Temozolomide Treating Patients With Breast Cancer Who Have Received Previous Treatment Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate objective response rate systemically CNS combination irinotecan hydrochloride temozolomide among patient breast cancer progressive brain metastasis progress previous treatment brain metastasis . - To determine toxicity associate combination irinotecan hydrochloride temozolomide breast cancer patient progressive brain metastasis . Secondary - To evaluate time first progression site ( CNS extra-CNS ) patient treat combination irinotecan hydrochloride temozolomide . - To evaluate overall survival patient treat combination irinotecan hydrochloride temozolomide brain metastasis . OUTLINE : Patients receive irinotecan IV day 1 15 oral temozolomide day 1-7 15-21 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer radiographically confirm metastasis brain Extracranial metastasis allow Must demonstrate progression brain metastasis prior treatment brain metastasis , include follow : External beam radiotherapy Brachytherapy Stereotactic radiosurgery Surgery Chemotherapy Treatments investigational drug , biologics , device Disease progression CNS must meet ≥ 1 follow criterion : New lesion CNS image study ( contrastenhanced CT scan MRI ) Progressive lesion image study ( contrastenhanced CT scan MRI ) New progressive lesion meet measurable disease definition allow Leptomeningeal disease allow concurrent progression parenchymal brain metastases Not candidate surgical resection and/or stereotactic radiosurgery Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 1 month Hemoglobin ≥ 10 g/dL ( transfusion allow ) ANC ≥ 1,500/mm³ Granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Must able swallow retain oral medication No active malignancy except follow : Curatively treat basal squamous cell carcinoma skin Carcinoma situ cervix Other malignancy consider diseasefree Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history immediate delayedtype hypersensitivity reaction gadolinium contrast agent contraindication gadolinium contrast No know contraindication MRI include , limited , follow : Cardiac pacemaker Implanted cardiac defibrillator Brain aneurysm clip Cochlear implant Ocular foreign body Shrapnel No active uncontrolled infection PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered side effect prior chemotherapy , surgery , radiotherapy extracranial disease brain metastases Concurrent trastuzumab , bisphosphonate , and/or corticosteroid therapy allow At least 1 week since prior current stable dose corticosteroid therapy Patients enzymeinducing antiepileptic agent ( EIAE ) valproic acid eligible switched alternate nonEIAE medication Concurrent coumadin allow No prophylactic use filgrastim ( GCSF ) first course treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>